175 related articles for article (PubMed ID: 8738588)
1. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
[TBL] [Abstract][Full Text] [Related]
2. A recombinant hirudin (IK-HIR02) in healthy volunteers. II. Effects on platelet adhesion and platelet-induced thrombin generation time.
Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
Haemostasis; 1996; 26(4):187-94. PubMed ID: 8872129
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
[TBL] [Abstract][Full Text] [Related]
4. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
5. Effects of a supersulfated low molecular weight heparin (IK-SSH) on different hemostatic parameters.
Glusa E; Barthel W; Schenk J; Radziwon P; Butti A; Markwardt F; Breddin KH
Haemostasis; 1998; 28(1):45-56. PubMed ID: 9885370
[TBL] [Abstract][Full Text] [Related]
6. Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers.
Esslinger HU; Köhne S; Radziwon P; Walenga JM; Breddin HK
Clin Appl Thromb Hemost; 2003 Jan; 9(1):79-88. PubMed ID: 12643328
[TBL] [Abstract][Full Text] [Related]
7. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters.
Zoldhelyi P; Webster MW; Fuster V; Grill DE; Gaspar D; Edwards SJ; Cabot CF; Chesebro JH
Circulation; 1993 Nov; 88(5 Pt 1):2015-22. PubMed ID: 8222093
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers.
Marbet GA; Verstraete M; Kienast J; Graf P; Hoet B; Tsakiris DA; Silling-Engelhardt G; Close P
J Cardiovasc Pharmacol; 1993 Sep; 22(3):364-72. PubMed ID: 7504125
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man.
Bichler J; Siebeck M; Fichtl B; Fritz H
Haemostasis; 1991; 21 Suppl 1():137-41. PubMed ID: 1716603
[TBL] [Abstract][Full Text] [Related]
10. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
Kouz J; Czech J; Nicolay U; Dickneite G
Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration.
Bichler J; Fichtl B; Siebeck M; Fritz H
Arzneimittelforschung; 1988 May; 38(5):704-10. PubMed ID: 3415713
[TBL] [Abstract][Full Text] [Related]
12. Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models.
Diehl KH; Römisch J; Hein B; Jessel A; Ronneberger H; Pâques EP
Haemostasis; 1995; 25(4):182-92. PubMed ID: 7557657
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
[TBL] [Abstract][Full Text] [Related]
14. Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393).
Thürmann P; Harder S; Kirchmaier CM
Eur J Clin Pharmacol; 1995; 48(3-4):241-6. PubMed ID: 7589048
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of recombinant hirudin.
Markwardt F; Nowak G; Stürzebecher J
Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans.
Fox I; Dawson A; Loynds P; Eisner J; Findlen K; Levin E; Hanson D; Mant T; Wagner J; Maraganore J
Thromb Haemost; 1993 Feb; 69(2):157-63. PubMed ID: 8456428
[TBL] [Abstract][Full Text] [Related]
18. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
19. A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection.
Zhao B; Zhang Y; Huang Y; Yu J; Li Y; Wang Q; Ma Y; Song HY; Yu M; Mo W
Thromb Haemost; 2017 Jan; 117(1):44-56. PubMed ID: 27904902
[TBL] [Abstract][Full Text] [Related]
20. Hirudin causes more bleeding than heparin in a rabbit ear bleeding model.
Klement P; Liao P; Hirsh J; Johnston M; Weitz JI
J Lab Clin Med; 1998 Sep; 132(3):181-5. PubMed ID: 9735923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
